Who founded Modulari-T?

Modulari-T was founded by David White, Stephanie Mok, David Cotnoir-White in 2021.

Who are Modulari-T's investors?

Modulari-T's investors include Gaingels, Metaplanet, Pioneer, Y Combinator, BoxOne Ventures, Red Rooster Ventures.

Where is Modulari-T headquartered?

Modulari-T is headquartered in Montreal, CA.

Modulari-T

YC W23

Montreal, CA · Founded 2021 · 4 employees · 6 known investors

Find your way into Modulari-T

Paths you didn't know you had: your email and LinkedIn already hold routes to the Modulari-T team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Modulari-T develops proprietary cell therapy technologies, including the MARC receptor and MoVe platform, based on primary research into immune system architecture. The company serves the cell therapy and immunotherapy market.

Also known as 12343096 CANADA INC. · 12343096 CANADA, INC. · Modulari-T Biosciences

Biotech Deep Tech Healthtech Medical Devices Gene Therapy Cell Therapy Synthetic Biology OncologyCanadaUnited States of AmericaAmerica / Canada

Founders & leadership· Y Combinator alumni (W23)

Modulari-T was founded in 2021 by David White, Stephanie Mok, and David Cotnoir-White.

David White Co-founder · President and CSODavid White completed a PhD where he researched protein receptors and their mechanisms for altering cellular behavior, which led him to found Modulari-T.

Stephanie Mok Co-Founder & COOStephanie Mok is co-founder and COO at Modulari-T, where she applies expertise in synthetic biology, 3D cell culture systems, and biomaterials. She holds a PhD in chemical engineering.

David Cotnoir-White Co-founder · President and CSO

David A. R. WhiteFounder

Delphine GuipouyHead of Immunology

Investors · 6

Gaingelslisted by GaingelsNew York · $200K – $500K

How we know: gaingels.com · Not right? Tell us

Metaplanetlisted by MetaplanetTallinn · $500K – $10M

How we know: Metaplanet's portfolio page · the VCSheet dataset · Y Combinator's founder network · Not right? Tell us

Pioneerlisted by PioneerToronto, Ontario

How we know: Y Combinator's founder network · pioneerfund.vc · open dataset · 5k.vc investor directory · Not right? Tell us

Y Combinatorlisted by Y CombinatorSan Francisco · $500K

How we know: the Y Combinator directory · open dataset · 5k.vc investor directory · Not right? Tell us

BoxOne VenturesreportedMontréal · $500K

How we know: the VCSheet dataset · Not right? Tell us

Red Rooster VenturesreportedSan Mateo

How we know: Y Combinator's founder network · Not right? Tell us

Related companies · 5

Eugit TherapeuticsTissue Targeting Therapies develops therapeutics targeting specific tissues using computational genomics and immunology. The company serves patients through drug development in the biotech/medtech space.

WhiteLab GenomicsWhiteLab Genomics uses AI and computational methods to analyze biological data and accelerate genomic drug discovery and development. The company serves pharmaceutical and biotech organizations seeking to reduce timelines and de-risk the development of genomic medicines.

Indee LabsIndee Labs develops Hydropore™, a non-viral microfluidic technology for delivering molecules, nucleic acids, proteins, and gene-editing complexes into immune cells for engineered cell therapy research and manufacturing. The platform enables rapid production of high-quality T-cell immunotherapies and other cell therapies with preserved cell function.

Modulo BioModulo is a biotech company focused on the neuroimmune system, developing treatments for brain and central nervous system disorders. It uses multiple neurobiology models and computational biology to study neuroimmune mechanisms and discover new therapies for patients affected by neurological disease.

CreateCREATE Medicines is a clinical-stage biotech company that develops in vivo mRNA immune cell programming therapies. The company focuses on RNA therapeutics and immune engineering for cancer, autoimmune disease, and transplant rejection applications.

Companies working in the same space as Modulari-T.

Legal entities · 2

corporate structure

12343096 CANADA INC.

12343096 CANADA, INC.

In the news

Modulari-T 🧬 Unleash the full power of the immune systemycombinator.com · Jan 2023

Frequently asked questions

What does Modulari-T do?: Modulari-T develops proprietary cell therapy technologies, including the MARC receptor and MoVe platform, based on primary research into immune system architecture. The company serves the cell therapy and immunotherapy market.
Who founded Modulari-T?: Modulari-T was founded by David White, Stephanie Mok, David Cotnoir-White in 2021.
Who are Modulari-T's investors?: Modulari-T's investors include Gaingels, Metaplanet, Pioneer, Y Combinator, BoxOne Ventures, Red Rooster Ventures.
Where is Modulari-T headquartered?: Modulari-T is headquartered in Montreal, CA.